NCT06751082Recruiting
Real World Observational Study of Sotatercept for Pulmonary Hypertension
Sotatercept Pulmonary Hypertension Observational Registry
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 20 Dec 2024
- Start date
- 20 Jan 2025
- Primary completion date
- Mar 2027
- Lead sponsor
- Mayo Clinic
- NCT number
- NCT06751082
What you commit to
- Study type: Observational
- Planned participants: 120
- From 20 Jan 2025 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Adults lacking capacity to consent
Who the study is looking for
- Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.